Dipal Doshi is the Chief Executive Officer at Entrada Therapeutics Inc., a biopharmaceutical company focused on developing transformative medicines for patients with genetic diseases. With a robust background in the life sciences industry, Doshi has played a pivotal role in steering Entrada Therapeutics towards its mission of creating novel therapies. Prior to joining Entrada, Doshi held various leadership positions at companies such as Biogen, where he served as Senior Vice President and Head of Corporate Strategy, and McKinsey & Company, where he was a Partner in the Pharmaceuticals and Medical Products practice. At Entrada Therapeutics, Doshi's leadership has been instrumental in advancing the company's pipeline of therapeutics, particularly those utilizing its proprietary intracellular delivery platform, known as the Endosomal Escape Vehicle (EEV). Under his guidance, Entrada has made significant strides in developing treatments for rare neuromuscular and other genetic disorders, bringing hope to patients who have limited or no treatment options. Doshi's strategic vision and deep understanding of the biotech landscape have been crucial in forging key partnerships and securing funding to support the company's growth and development. Doshi's achievements extend beyond his current role at Entrada Therapeutics. He has been recognized for his contributions to the industry, including being named one of the "Top 50 Healthcare Technology CEOs" by The Healthcare Technology Report. His expertise in corporate strategy, business development, and innovation has made him a respected figure in the biopharmaceutical sector. As CEO, Doshi continues to lead Entrada Therapeutics with a focus on scientific excellence and patient-centric innovation, driving the company forward in its quest to deliver life-changing therapies.